Approval · Notice of Compliance 19443 · 2017
BELBUCA: Notice of Compliance 19443
Issued June 21, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19443
- Date
- June 21, 2017
- Company
- Paladin Labs Inc
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
Medicinal ingredients
- BUPRENORPHINE HYDROCHLORIDE 75 MCG per DOSE
- BUPRENORPHINE HYDROCHLORIDE 150 MCG per DOSE
- BUPRENORPHINE HYDROCHLORIDE 300 MCG per DOSE
- BUPRENORPHINE HYDROCHLORIDE 450 MCG per DOSE
- BUPRENORPHINE HYDROCHLORIDE 600 MCG per DOSE
- BUPRENORPHINE HYDROCHLORIDE 750 MCG per DOSE
- BUPRENORPHINE HYDROCHLORIDE 900 MCG per DOSE